Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial
Laura Barr, Manohursingh Runglall, Jad Othman, Hughes de Lavallade et al.
Journal
Haematologica
Topics
Acute Myeloid Leukemia Research
article
Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial
Laura Barr, Manohursingh Runglall, Jad Othman, Hughes de Lavallade, Jelena Jovanovic, Phoebe Aucken, Nigel Russell, Nicola Potter, Richard Dillon, Patrick Harrington, Michael Lim, Carlos Jiménez-Vicente, Jennifer O’Sullivan
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Guy's Hospital (GB), King's College - North Carolina (US), King's College London (GB), King's College Hospital (GB)
Funders
Amgen, Pfizer, Royal College of Pathologists of Australasia, Syndax Pharmaceuticals, Astellas Pharma, RCPA Foundation